930122-19-3

Basic information

• Product Name: 4-(2-methoxy-2-oxoethyl)-3-oxopiperazine-1-carboxylic acid tert-butyl ester
• Synonyms: 4-(2-methoxy-2-oxoethyl)-3-oxopiperazine-1-carboxylic acid tert-butyl ester
• CAS NO: 930122-19-3
• Molecular Weight: 272.301
• Mol File: 930122-19-3.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: 4-(2-methoxy-2-oxoethyl)-3-oxopiperazine-1-carboxylic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(2-methoxy-2-oxoethyl)-3-oxopiperazine-1-carboxylic acid tert-butyl ester(930122-19-3)
• EPA Substance Registry System: 4-(2-methoxy-2-oxoethyl)-3-oxopiperazine-1-carboxylic acid tert-butyl ester(930122-19-3)

Safety Data

• Hazardous Substances Data: 930122-19-3(Hazardous Substances Data)

Upstream product

• 76003-29-7 4-(t-butyloxycarbonyl)piperazin-2-one 
• 96-32-2 bromoacetic acid methyl ester 

Downstream Products

• 32705-79-6 2-(2-oxopiperazin-1-yl)acetic acid methyl ester 

Relevant articles and documents

Introduction of substituents on the 2-oxo-piperazine skeleton by [3+2] cycloaddition and subsequent transformation

The 3,4-substituted 2-oxo-piperazines 5-9 are obtained by [3+2] cycloaddition from nitrone 1 and a variety of alkenes. Subsequent functionalization of the bicyclic adducts involves reductive N-O bond cleavage. A route towards libraries of immobilized 1,3-aminoalcohols with a 3,4-substituted 2-oxo-piperazine scaffold is briefly discussed for adducts derived from N-substituted maleic imides.

Dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase

The invention provides dimer amide micromolecule PROTACs for inducing MDM2 to self-degrade E3 ubiquitin ligase. The structure of the PROTACs is shown in the specification, wherein in a compound (I), L1 is C1-C30 linear or branched alkyl with or without a substituent group, and any carbon atom in L1 is optionally replaced by heteroatom; R1, R2, R3 and R4 are C1-C30 linear or branched alkyl with orwithout a substituent group, C1-C30 aryl with or without a substituent group, C1-C30 linear or branched alkylaryl with or without a substituent group or C1-C30 linear or branched aryl alkyl with or without a substituent group respectively and independently; X1, X2, X3 and X4 are halogen respectively and independently.

MACROCYLIC PYRIMIDINE DERIVATIVES

The present invention relates to substituted macrocylic pyrimidine derivatives of Formula (I) wherein the variables have the meaning defined in the claims. The compounds according to the present invention have EF2K inhibitory activity and optionally also Vps34 inhibitory activity. The invention further relates to processes for preparing such novel compounds, pharmaceutical compositions comprising said compounds as an active ingredient as well as the use of said compounds as a medicament.